Moffitt Cancer Center's planning and evaluation of research activities encompass 3 internal and 1 external advisory bodies, as well as ad hoc consultants as needed. Moffitt requests $75,000 to support a portion of these activities, including $70,000 in the category of Consultant Costs and $5,000 in the category of Other Expenses. All advisory bodies report to the Center Director. Each Associate Center Director meets at least monthly with the Center Director and together, they take a lead role in overseeing the planning and evaluation process. These advisory bodies have successfully guided the rapid growth of research over the past decade, and the requested support will continue to enhance these efforts. Moffitt's external advisory board, the Council of Scientific Advisors, reviews the Center's scientific progress in terms of the CCSG by evaluating the research programs, shared resources, scientific and institutional accomplishments, and future plans for sustaining and increasing research growth. It also evaluates the annual research accomplishments relative to the state mandate and reports its findings to the Center's Board of Directors and state officials. Ad hoc advisors advise Moffitt on refining strategic research areas, evaluating its methods, and suggest ways to better organize specific efforts. Moffitt also requests funds for the Center's annual Scientific Retreat. The all day event pulls together faculty, postdoctoral fellows, and students to showcase research from all areas (basic, population, clinical investigations, and translational) and includes an outside keynote speaker.

Public Health Relevance

Moffitt's success relies on long-term strategic planning and evaluation and funds for this category are critical to Moffitt success. In particular, the recommendations of external advisors have been vital to strengthening the research enterprise.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Poort, Hanneke; Meade, Cathy D; Knoop, Hans et al. (2018) Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs 41:E28-E37
Pamnani, Shitaldas J; Sudenga, Staci L; Rollison, Dana E et al. (2018) Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis 218:1219-1227
Dai, Juncheng; Li, Zhihua; Amos, Christopher I et al. (2018) Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis :
Cherezov, Dmitry; Hawkins, Samuel H; Goldgof, Dmitry B et al. (2018) Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial. Cancer Med 7:6340-6356

Showing the most recent 10 out of 1254 publications